MGO One Seven LLC Sells 167 Shares of DexCom, Inc. $DXCM

MGO One Seven LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,100 shares of the medical device company’s stock after selling 167 shares during the quarter. MGO One Seven LLC’s holdings in DexCom were worth $358,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC grew its position in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. State of Alaska Department of Revenue grew its position in DexCom by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 45,740 shares of the medical device company’s stock valued at $3,123,000 after acquiring an additional 1,205 shares during the last quarter. GAM Holding AG grew its position in DexCom by 17.3% in the 1st quarter. GAM Holding AG now owns 11,177 shares of the medical device company’s stock valued at $763,000 after acquiring an additional 1,647 shares during the last quarter. Praxis Investment Management Inc. grew its position in DexCom by 3.3% in the 1st quarter. Praxis Investment Management Inc. now owns 11,910 shares of the medical device company’s stock valued at $813,000 after acquiring an additional 380 shares during the last quarter. Finally, First American Bank grew its position in DexCom by 2.8% in the 1st quarter. First American Bank now owns 26,988 shares of the medical device company’s stock valued at $1,843,000 after acquiring an additional 725 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock opened at $66.60 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock has a market capitalization of $26.12 billion, a price-to-earnings ratio of 46.25, a P/E/G ratio of 1.40 and a beta of 1.47. The stock has a fifty day simple moving average of $73.35 and a two-hundred day simple moving average of $77.58. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the business earned $0.43 EPS. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several research analyst reports. Truist Financial cut their price objective on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler upped their price objective on DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research report on Thursday, July 31st. UBS Group upped their price objective on DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Argus initiated coverage on DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price for the company. Finally, Morgan Stanley upped their target price on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,849 shares of company stock valued at $564,733. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.